Namodenoson
Unknown / undisclosed
Evidence outlook · registrational
Hepatocellular Carcinoma: registrational readout pending
Its supporting mid-stage studies have completed. The registry's posted readout date (2026-02) has passed without a status update. Check News for topline announcements.
Also in development:MASH / NASH · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
LIVERATION NCT05201404 · Hepatocellular Carcinoma Registry: NCT05201404 | 3 | Overall Survival (OS) (From the time of randomization until the date of death from any cause, assessed up to 60 months) 2026-02 | In progress: primary completion was expected 1 Feb 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
Other Adenosine A3 receptor drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Hepatocellular Carcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Namodenoson: this drug | Phase 3 | — | Adenosine A3 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | NCT01908426: Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4) | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT03062358: Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1) | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT02435433: Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07) | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Approved | Monoclonal antibody | CTLA-4 | Partial signal | No reviewed efficacy summary in this indication | |
| Amezalpat | Phase 3 | Small molecule | PPARα (peroxisome proliferator-activated receptor alpha) | not yet graded | No reviewed efficacy summary in this indication | |
| Apatinib | Phase 3 | Small molecule | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| BGB-B2033 | Phase 3 | Multispecific antibody | GPC3 (glypican-3) x 4-1BB (CD137) | not yet graded | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| JS207 | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Nilvanstomig | Phase 3 | Biologic (subtype unspecified) | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Pegargiminase | Phase 3 | Protein / enzyme therapeutic | Arginine-depleting pegylated arginine deiminase | not yet graded | No reviewed efficacy summary in this indication | |
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Piclidenoson | Phase 3(overall) | Small molecule | Adenosine A3 receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| RYZ801 | Phase 1/2 | Radiopharmaceutical | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-324 | Phase 1 | Antibody–drug conjugate | Glypican-3 (GPC3) / Topoisomerase I | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| SENTI-301A | Phase 1 | Cell therapy | GPC3 (CAR-NK, calibrated IL-15) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2524 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| AZD7003 | —(overall) | Cell therapy | Glypican-3 (GPC3) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent